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One of the most effective and widely used methods for preparation of modified re-
lease systems is the production of matrix tablets, composed of the drug and polymeric
carrier, enabling sustained drug release (1). The development of modified release dosage
forms for weakly basic drugs is an important technological challenge. Basic drugs are
characterized by pH-dependent solubility, which could significantly influence their re-
lease in the gastro-intestinal (GI) tract (2, 3). The drug pKa value defines its ability to be
deprotonated in intestinal fluids, as well as its solubility and release rate (4). This is why
it is crucial to provide pH-independent release of such drugs (5, 6). Various approaches
have been applied: (i) addition of organic acids (2, 5); (ii) using a combination of a hy-
drophilic and an enterosolvent polymer (4, 5, 7); (iii) polymer, whose swelling behavior
depends on pH and the ionic strength of the medium. Polyzwitterions (PZIs) are poly-
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mers whose swelling depends strongly on ionic strength. There are some studies (8, 9)
on the synthesis and properties of PZIs as matrices for drug delivery. PZI’s self-associa-
tion determines their interactions with low-molecular zwitterions (10) and surfactants
(11) as their physico-mechanical properties (12). Their self-association in an aqueous so-
lution is due to the dipole-dipole interactions, leading to the formation of dipole-dipole
clusters (DDC) (the left hand side in Fig. 1) (13–18). These DDCs are destroyed in the
presence of a low-molecular-mass salt (LMS) and the PZI macromolecules swell (Fig. 1).
This is the essence of the antipolyelectrolyte effect (APE) (11, 15, 16). Upon swelling of
the PZI macromolecules, the hydrophobic fragments are associated in hydrophobic co-
res, coated with a hydrophilic shell, consisting of co-ions and their atmosphere (the right
hand side in Fig. 1) (16, 19, 20).
The aim of this study was to evaluate the feasibility of the newly synthesized PZIs
latex based on vinyl acetate (VA)-co-3-dimethyl(methacryloyloxyethyl)ammonium pro-
pane sulfonate (DMAPS) [p(VA-co-DMAPS)s] as a matrix carrier for verapamil hydro-
chloride. Thus far, no data about the preparation and application of p(VA-co-DMAPS) as
a matrix for drug delivery could be found. Verapamil hydrochloride is an L-type cal-
cium channel blocker with a class IV antiarrythmic activity (21).
EXPERIMENTAL
Materials
Vinyl acetate (VA) (Merck, Germany) was purified by vacuum distillation. 3-Dime-
thyl(methacryloyloxyethyl)ammonium propane sulfonate (DMAPS) (Merck, Germany)
was used as obtained. The initiator potassium peroxide disulfate (KPS, Fluka, Switzer-
land) was purified by recrystallization from water. Verapamil hydrochloride was sup-
plied by Knoll AG, Germany. Kollidon® SR (polyvinylacetate-polyvinylpyrrolidone,
BASF AG, Germany) was used as polymer matrix. Magnesium stearate was used as lu-
bricant (Herwe Chemisch-technische Erzeugnisse, Germany) and silica colloidal dioxide
as glidant (Aerosil 200) (Degusa, Germany).
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Fig. 1. Reversible destruction of the
zwitterionic dipole-dipole clusters
(junction points) to single self-neu-
tralizing ionic parts by increasing the
ionic strength, and self-association of
the PZI macromolecules as amphi-
philic structures with a hydrophobic
core and a hydrophilic shell after the
addition of LMS into aqueous solu-
tions.
Methods
Emulsifier-free emulsion co-polymerization of VA and DMAPS. – Emulsifier-free emul-
sion copolymerization (EFC) of VA and DMAPS was performed in water using the me-
thod described in our previous paper (22). The VA/DMAPS mole ratios in the monomer
feed were 90/10 (co-polymer 1), 85/15 (co-polymer 2), 80/20 (co-polymer 3) and 70/30
(co-polymer 4). p(VA-co-DMAPS)s were obtained as white porous powders, insoluble in
water and in most organic solvents.
Elemental analysis. – The co-polymer composition was determined by nitrogen ana-
lysis using a Vario EL III elemental analyzer (Elementar Analysensysteme GmbH, Ger-
many).
Swelling kinetics of p(VA-co-DMAPS). – The lyophilized co-polymers 1–4 were mol-
ded into tablets of 7 mm diameter and 2 mm height. The swelling degree (Q) of the co-
-polymer samples was determined in an aqueous solution (pH 1.2 – 0.1 mol L–1 HCl)
and in a phosphate buffer solution (PBS) (pH 6.8 – Na2HPO4  2H2O  KH2PO4) at 37 °C.
The ionic strength at pH 1.2 was 0.100 mol L–1 and 0.136 mol L–1 in PBS. The mass of dry
samples was determined after drying in a vacuum oven (60 °C) to constant mass. The
dried co-polymer tablets were placed into 20-mL aqueous solution (pH 1.2) and in PBS
(pH 6.8). The mass of wet samples was determined after removal of surface water by
blotting with filter paper. For each co-polymer, the average value of Q was calculated
from three tablets.
Preparation of matrix tablets. – Sustained release (SR) tablets were prepared using po-
lymer carriers: (i) p(VA-co-DMAPS); (ii) Kollidon® SR. All tablets contained 120 mg ve-
rapamil hydrochloride, 125 mg co-polymers 1 to 4 or Kollidon® SR, 1% (m/m) magne-
sium stearate and 1% (m/m) silica colloidal dioxide. The Kollidon® SR matrix tablets
were prepared by the method of direct compression, and p(VA-co-DMAPS) matrix tab-
lets were prepared by wet granulation.
Preparation of direct compression matrix tablets. – Direct compression matrix tablets
were prepared using the polymer carrier Kollidon SR with verapamil hydrochloride as
follows: verapamil hydrochloride and Kollidon SR were dry mixed in a HLSH2-6 high
shear mixing granulator (Bamtri, China) for 25 min at 300 rpm. Magnesium stearate and
silica colloidal dioxide (Aerosil 200) were added and mixed for another 5 min. The blend
obtained was tableted to 250 mg using a set of 9 mm-diameter standard concave pun-
ches and a single punch tablet press (EK 0, Korsch, Germany).
Preparation of wet granulation matrix tablets. – Wet granulated tablets with verapamil
hydrochloride and p(VA-co-DMAPS) were prepared by dry mixing of both compounds
using a HLSH2-6 high shear mixing granulator (Bamtri, China) for 25 min at 300 rpm.
Isopropanol was added as a wetting agent dropwise under stirring at 500 rpm. The mix-
ture obtained was granulated and passed through a 1500-mm sieve. The granules obtai-
ned were spread evenly on a tray and dried for 8 h at 40 °C. Each granule formulation
was passed through an 800-mm sieve and dry-blended with magnesium stearate and sili-
ca colloidal dioxide (Aerosil 200) for 5 min. The resultant blend was tableted as stated
for direct compression matrix tablets.
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In vitro drug dissolution studies. – Drug release profiles were evaluated using a disso-
lution test apparatus (Erweka DT 600, Germany). The USP paddle method was applied
(23). The test was carried out at a paddle rotation speed of 50 rpm, in 900 mL dissolution
medium maintained at 37 ± 0.5 °C at three different pH values: (i) pH 1.2; (ii) pH 6.8; (iii)
throughout the release experiments, pH was changed in order to evaluate the effect of
pH (ionic strength) modification. For this purpose, the tablets were first immersed in 0.1
mol L–1 HCl solution (pH 1.2) for 2 h and were then transferred into PBS solution (pH
6.8) for 6 h. Five mL aliquots of dissolution media were withdrawn at selected intervals
up to 8 h. Each sample was filtered through a 0.45-mm membrane filter (Sartorius cellu-
lose acetate filter, Germany). The quantity of the drug in the sample solution was deter-
mined by UV spectroscopy (absorbance at 278  2 nm) using a Hewlett-Packard 8452 A
Diode Array spectrophotometer (USA). The cumulative percentage of drug release was
calculated and the average of six determinations was used in the data analysis.
RESULTS AND DISCUSSION
Characterization of the p(VA-co-DMAPS) co-polymers
A new p(VA-co-DMAPS) latex with different compositions has been synthesized by
EFC. The preliminary screening of p(VA-co-DMAPS) matrices suggested that only four
co-polymer compositions (1–4) exhibit the desired verapamil hydrochloride release.
Their characteristics are given in Table I. The results show that the co-polymers are en-
riched in DMAPS units. One of the most significant results obtained is that although no
emulsifier was used, the obtained microspheres were of small average diameter (200 nm).
This is especially important for the performance of these co-polymers as sustained drug
delivery matrices. This effect could be related to the favourable co-monomer hydropho-
bic-hydrophilic ratio in the copolymerization mixture.
Swelling behavior of p(VA-co-DMAPS) matrices
In general, Q is related to the osmotic pressure, cross-linking density and co-poly-
mer affinity to adsorb water (24). Being a zwitterionic monomer, DMAPS has a zero total
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1 90 1.73 86.03
2 85 2.30 80.00
3 80 2.74 73.00
4 70 2.92 67.99
a Total monomer concentration: 7.5 x 10–2 mol L–1; [KPS]: 1% (m/m); solvent: distilled water;
temperature: 49  1 °C; VA – vinylacetate.
monomer charge, so the main effect on Q is the affinity to water. The ability of the p(VA-
co-DMAPS) matrix to swell in aqueous solutions depends on the mole fraction of DMAPS
units in the co-polymer (mDMAPS), pH (ionic strength). It could be assumed that by vary-
ing mDMAPS and ionic strength, it should be possible not only to change the swelling de-
gree of p(VA-co-DMAPS)s, but also to control the rate of drug release in the GI tract.
The Q values of p(VA-co-DMAPS) matrices as a function of time at pH 1.2 and 6.8 at
37 °C are shown in Figs. 2a and b. As it is seen in Figs. 2a and b, Q values increase rap-
idly and then decrease. This process is more clearly pronounced at pH 1.2. This pheno-
menon is known as »overshooting« and is attributed to the slow macromolecular relax-
ation (24). From the dependencies in Figs. 2a and b, it can be clearly seen that the »over-
shooting« phenomenon has been observed by all co-polymers. At a high diffusion rate
of both water and LMS molecules in the co-polymer matrix, the large macromolecules
have not enough time to rearrange to the equilibrium structural organization, specific to
each co-polymer. Large numbers of intermolecular bonds are destroyed during this fast
diffusion and their recovery to reach the above mentioned equilibrium structural organi-
zation leads to a decrease in the Q value. The DDC (the left hand side in Fig. 1) repre-
sents the physical nodes between different fragments of the co-polymer macromolecule
or between different macromolecules. The relationship between these junctions, which
could be reversibly destroyed to single self-neutralizing ionic pairs (IPs) (Fig. 1), and the
»overshooting« phenomenon is quite interesting.
At the beginning (before immersion of the co-polymer tablets 1–4 into an aqueous
solution), most of the zwitterionic units (ZIs) in the co-polymer tablets 1–4 are in IPs
form, while the small number of DDC act as physical nodes. When the co-polymer tab-
lets are immersed into an aqueous solution, IPs are first hydrated, since they are more
evenly distributed and more accessible. The VA units are hydrophobic and not hydrated.
Water molecules diffuse at a higher rate because of the high initial concentration gradi-
ent. The hydrated IPs form a phase (hydrophilic phase) separated from the total mass of
VA hydrophobic units. The process of two-phase formation, hydrophobic (VA units) and
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Fig. 2. Swelling kinetics of p(VA-co-DMAPS) matrices at pH: a) 1.2 and b) pH 6.8 (37 °C); () co-poly-
mer 1; () co-polymer 2; () co-polymer 3; () co-polymer 4 (mean  SD, n = 3).
hydrophilic (hydrated IPs) is hindered by DDC-physical nodes. Therefore, the effect of
both ionic strength and mDMAPS on the DDC destruction to IPs (Fig. 1) also affects the
»overshooting« phenomenon.
The dependencies in Figs. 2a and b and the data from Table II show that at pH 1.2
the Qmax values for all co-polymers are lower than at pH 6.8. The higher ionic strength at
pH 6.8 (ionic strength = 0.136 mol L–1) contributes to easier destruction of DDC to IPs
(Fig. 1), resulting in higher swelling of the p(VA-co-DMAPS) matrices.
Despite the relatively narrow limits of mDMAPS, the changes of its values affect the
swelling kinetics of the p(VA-co-DMAPS) matrices. From Figs. 2a and b, it can be seen
that with increasing mDMAPS in co-polymers 1–4, the Qmax values also increase at both
pH values. The plot for co-polymer 4 at both pH values is quite different from the plots
obtained for co-polymers 1 to 3. The action of mDMAPS is twofold: (i) it enhances the
hydrophilicity of the co-polymer matrix (especially for co-polymer 4, exhibiting the
highest mDMAPS value); (ii) increases DDC density, size and precision in the co-polymer
matrices 2, 3 and 4. For co-polymer 4 (highest mDMAPS), a markedly extended relaxation
time (tmax) was observed at both pH 1.2 and 6.8 (Table II). This could be attributed to the
higher DDC concentration (in co-polymer 4), their slower destruction and probably
slower relaxation.
The Qmax value is reached after the microphase separation into hydrophobic and hy-
drophilic parts has taken place. In the hydrophilic (swollen) part of the co-polymer ma-
trix, the IPs concentration increases, which helps the equilibrium shift to the left (Fig. 1),
leading to the formation of new physical nodes in the aqueous (swollen) phase, contrib-
uting to its shrinkage – the Q value decreases. Furthermore, the lower the ionic strength,
the higher the probability of physical nodes creation; the p(VA-co-DMAPS) matrices
shrink more and the Q value decrease is more strongly pronounces. These results were
obtained at pH 1.2 (ionic strength = 0.100 mol L–1) (Fig. 2a).
The dependencies in Figs. 2a and b, showing the swelling behavior of p(VA-co-
DMAPS) matrices, could be explained as follows. The swelling kinetics of p(VA-co-DMAPS)
matrices shows a close relation between the »overshooting« phenomenon and DDC for-
mation, typical of co-polymers with zwitterionic units. Perhaps, the influence of the
DDC reversible destruction (Fig. 1) on the specific »overshooting« phenomenon is the-
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Table II. Qmax and relaxation time (tmax) values of p(VA-co-DMAPS) matricesa
Co-polymer
No.
Qmax at pH 1.2
(%)
Qmax at pH 6.8
(%)
tmax at pH 1.2
(h)
tmax at pH 6.8
(h)
1 62.05 64.01 0.50 0.5
2 65.98 69.88 0.45 1.0
3 69.95 72.78 0.50 1.0
4 81.97 91.46 1.50 2.0
a Temperature: 37 °C
reby explained for the first time. The above discussed results reveal that mDMAPS and
ionic strength (LMS) affect the reversible equilibrium between DDC and IPs (Fig. 1), de-
fining the Q value.
Release of verapamil hydrochloride from tablets with p(VA-co-DMAPS) matrices
Verapamil hydrochloride, characterized by pKa = 8.6 (25), was chosen as a model
drug. It is soluble in water (82 mg mL–1 at pH 2.32, 11 mg mL–1 at pH 6.76 (26), and
practically insoluble in basic solutions (27).
The composition of the p(VA-co-DMAPS)-based tablet formulations studied is shown
in Table III. Kollidon® SR-based model formulations were used as reference.
The release profiles of verapamil hydrochloride from the model p(VA-co-DMAPS)
tablets at pH 1.2 and pH 6.8 are presented in Figs. 3a and b. The dependencies show the
influence of the mDMAPS values on the release profiles after 6 h. The amount of drug re-
leased from co-polymer 4-based formulation at pH 1.2 reached 73.4% after 8 h. This re-
sult suggests that the high solubility of verapamil hydrochloride at pH 1.2 leads to a
higher release rate despite the lower swelling degree of the p(VA-co-DMAPS) matrices
at this pH.
At pH 6.8 (Fig. 3b), the release rate could be expected to be markedly lower. How-
ever, the results obtained (Fig. 3b) do not confirm this assumption – after 8 h the amount
of drug released from co-polymer 4-based matrices reached 51.7%. This result could be
explained by the effect of APE (the presence of LMS and higher ionic strength at pH 6.8)
on the swelling degree of p(VA-co-DMAPS) matrices. This high swelling degree com-
pensates for the very low solubility of verapamil hydrochloride at this pH.
The drug release profiles from the four model p(VA-co-DMAPS) matrices and the
matrix based on Kollidon® SR were investigated under varying pH values as well (Fig.
4). First, both p(VA-co-DMAPS) and Kollidon® SR tablets were put for 2 h in dissolution
media with pH 1.2, then for 6 h at pH 6.8. The results obtained (Fig. 4), show that with
increasing mDMAPS in the p(VA-co-DMAPS) matrices, the verapamil hydrochloride re-
lease rate was also increased. The difference between the release rates for co-polymers 1
and 4 after 8 h is about 6.5%. The mDMAPS increase in p(VA-co-DMAPS) tablets results in
enhanced possibility of DDC destruction as well as a higher swelling rate. The equilib-
rium in Fig. 1 is shifted to IPs, which permits faster diffusion of verapamil hydrochlo-
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1 120 125 1 1
2 120 125 1 1
3 120 125 1 1
4 120 125 1 1
Kollidon® SR 120 125 1 1
ride from the gel structure. Hence, the release profile of verapamil hydrochloride can be
modified just by varying mDMAPS in p(VA-co-DMAPS)s.
The results presented in Fig. 4 clearly indicate that all p(VA-co-DMAPS) matrices re-
lease verapamil hydrochloride at higher rates compared to Kollidon® SR. After 8 h, ma-
trices based on p(VA-co-DMAPS) released 49.8% to 56.1% verapamil hydrochloride,
while the amount of released drug from Kollidon® SR matrix was only 39.5%. The differ-
ence in the amount of released verapamil hydrochloride after 8 h from Kollidon® SR ma-
trix and co-polymer 4 (higher mDMAPS) is more than 16% while in case of co-polymer 1,
this difference is only 10%. These values could be attributed mainly to the PZI character
of the p(VA-co-DMAPS) matrix. In the case of Kollidon® SR matrix [a physical mixture
of poly(VA) and poly(N-vinyl pyrrolidone) poly(NVP)], the swelling behavior is pH-in-
dependent. However, this behavior of the Kollidon® SR matrix (without addition of sub-
sidiary materials like enterosolvent polymers and organic acids) is not favorable in the
case of verapamil hydrochloride and this is the reason for its low release rate. The pre-
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Fig. 4. Release kinetics of verapamil hydro-
chloride from model p(VA-co-DMAPS) tablets
and from Kollidon® SR at pH 1.2 (the first 2
hours) and at pH 6.8 (after the second hour)
(37 °Ñ); () co-polymer 1; () co-polymer 2; ()
co-polymer 3; () co-polymer 4; () Kollidon®
SR (mean  SD, n = 6).









































Fig. 3. Release kinetics of verapamil hydrochloride from model p(VA-co-DMAPS) tablets at pH: a)
1.2 and b) pH 6.8 (37 °C); () co-polymer 1; () co-polymer 2; () co-polymer 3; () co-polymer 4
(mean  SD, n = 6).
sented results demonstrate the advantages of the newly synthesized p(VA-co-DMAPS)
matrices. Due to their specific zwitterionic structure, higher drug release in the GI tract
could be achieved.
According to Streubel et al. (5) ethyl cellulose polymer matrices released 34% vera-
pamil hydrochloride after 8 h at pH 6.8. The same authors explained that formulations
based on the intensively swelling HPMC in 1:1 ratio (m/m) to lactose in these conditions
released only 17% of the drug after 8 h. The comparison of these release profiles with
our results shows that p(VA-co-DMAPS)s, especially those with higher mDMAPS (co-po-
lymers 3 and 4), are effective and suitable matrices for incorporation of verapamil hy-
drochloride and possibly of other drugs with similar physicochemical properties.
CONCLUSIONS
It has been established that the newly synthesized p(VA-co-DMAPS)s are promising
candidates for matrix carriers of verapamil hydrochloride and possibly of other drugs
with basic properties. Specific structure organization of a p(VA-co-DMAPS)s permits to
solve the problems associated with the release behavior and makes them advantageous
over other polymer matrices.
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S A @ E T A K
Novi kopolimerni zwitterionski matriksi za polagano osloba|anje
verapamil hidroklorida
BISTRA KOSTOVA i DIMITAR RACHEV
Metodom emulzijske polimerizacije sintetiziran je novi stabilni kopolimer [vinil
acetat-ko-3-dimetil(metakriloiloksietill)amonijev propan sulfînat, p(VA-co-DMAPS)] la-
teks promjenjivog sastava. Neobi~no »pretjerano« pona{anje tableta pripravljenih iz tog
kopolimera obja{njava se stvaranjem specifi~nih klastera suprotno orijentiranih dipola 
zwitterionskih specija. Prou~avan je utjecaj njihovih koncentracija s udjelom DMAPS je-
dinica (mDMAPS), pH i ionskom jakosti na kinetiku bubrenja. Dobiveni rezultati do-
kazuju da se promjenom mDMAPS i ionske jakosti mo`e kontrolirati stupanj bubrenja
p(VA-co-DMAPS) matriksa i osloba|anje verapamil hidroklorida iz tableta pa se ti ma-
triksi mogu upotrijebiti za polagano osloba|anje bazi~nih lijekova srodnih verapamilu.
Klju~ne rije~i: kopolimer [vinil acetat-ko-3-dimetil(metakriloiloksietill)amonijev propan sul-
fînat, emulzijska kopolimerizacija bez emulgatora, polizwitterion, dipol-dipol klasteri,
bubrenje, matriksne tablete, isporuka lijekova
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